drugset / Trial / NCT00843310
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side effects than similar combination induction treatment.
Timeline
- Start
- 2008-11
- Primary completion
- 2011-10
- Completion
- 2011-10
Outcome
Outcome not reported
Stopped (Enrollment): “Due to slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | — |
| Background | Melphalan | Small molecule | 4 mg/m2 | — |